Back to Search
Start Over
How can we manage the cardiac toxicity of immune checkpoint inhibitors?
- Publication Year :
- 2021
-
Abstract
- Introduction: Cancer immunotherapies with monoclonal antibodies (mAbs) against immune checkpoints (i.e. CTLA-4 and PD-1/PD-L1) have revolutionized antineoplastic treatments. Immune checkpoint inhibitors (ICIs) approved for cancer immunotherapy are mAbs anti-CTLA-4 (ipilimumab), anti-PD-1 (nivolumab, pembrolizumab, and cemiplimab), and anti-PD-L1 (atezolizumab, avelumab, and durvalumab). Treatment with ICIs can be associated with immune-related adverse events (irAEs), including an increased risk of developing myocarditis. These findings are compatible with the observation that, CTLA-4, PD-1, and PD-L1 pathways play a central role in the modulation of autoimmunity.Areas covered: In this paper, we start from examining the pathogenesis of cardiovascular adverse events from ICIs, and then we focus on risk factors and strategies to prevent and manage this cardiotoxicity.Expert opinion: There is a growing need for a multidisciplinary approach of ICI-associated cardiotoxicity, involving oncologists, cardiologists, and immunologists. Prevention and effective management of ICIs cardiotoxicity starts with an in-depth screening and surveillance strategies of high-risk patients, in order to improve early detection and appropriate management in a personalized approach
- Subjects :
- cardiac toxicity
medicine.drug_class
animal diseases
Immune checkpoint inhibitors
Immune Checkpoint Inhibitor
chemical and pharmacologic phenomena
030204 cardiovascular system & hematology
Monoclonal antibody
03 medical and health sciences
0302 clinical medicine
Immune system
Antineoplastic Agents, Immunological
Risk Factors
Neoplasms
Cardiac toxicity
medicine
immune-related adverse event
Humans
Pharmacology (medical)
Immune Checkpoint Inhibitors
Cancer
business.industry
Antibodies, Monoclonal
General Medicine
biochemical phenomena, metabolism, and nutrition
medicine.disease
Immune checkpoint
Cardiotoxicity
030220 oncology & carcinogenesis
Cancer research
immune-related adverse events
bacteria
Neoplasm
Immunotherapy
biological phenomena, cell phenomena, and immunity
business
Human
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....1643f4145a7b5ef383e12302b9c207c2